Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow.
GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves capturing on a microfluidics platform the complete B-cell populations of five to ten people who have recovered COVID-19 and mounted a robust immune response to the virus. The associated antibody-encoding genes are then transferred into a mammalian cell line.
Read the full story.